-
Federal incentive for pharmaceutical companies to study drugs in children has led to improved labeling for several medications. More needs to be done, though, and pharmacists can play a key role in encouraging the process, says one pediatrician.
-
The overuse of antibiotics in children may be subsiding, according to a study published in the September issue of Pediatrics.
-
Two recent warnings have led to concerns about the risks of prescribing antidepressants to children.
-
These drugs recently received final approval from the U.S. Food and Drug Administration (FDA):
-
Gemifloxacin is effective as standard treatment for the treatment of ABECB and CAP; however, in limited trials it does not seem to be more efficacious or safe than other standard drug therapy for these indications.
-
Extended hormonal contraception is drawing dramatic attention due to the desire of many women to reduce or eliminate the number of withdrawal bleeds associated with current birth control methods.
-
The final version of the recently proposed changes to the Emergency Medical Treatment and Labor Act (EMTALA) takes effect Nov. 10.
-
-
There are arguments about the optimal treatment for ulcers with nonbleeding visible vessels and adherent clots. This study showed that the combination of endoscopic hemostasis with IV proton pump inhibitor therapy is superior to PPI alone in management of such patients.
-
Vardenafil has been approved for the treatment of erectile dysfunction in men. The drug is the second oral type 5 phosphodiestase (PDE5) inhibitor approved for this indication along with sildenafil (Viagra).
